NEW YORK ─ Harvard University spinout Torus Biosystems is planning its entry into the market for syndromic multiplex testing, leveraging a platform that combines convection PCR, nanoarrays, and proprietary probes to enable quantitative detection of a broad range of DNA and RNA biomarkers.
Torus is combining the technologies to develop diagnostic testing products for use near patients that would provide results directly from a sample within 30 minutes, its President and CEO Shawn Marcell said in an interview.